# Activation of TRPV3 channels in bladder cancer cells stimulates ATP release

**Authors:** Jonas Janenz, Andrea Leipe, Nicole Urban, Michael Schaefer, Kerstin Hill

PMC · DOI: 10.1016/j.molpha.2025.100096 · Molecular Pharmacology · 2025-11-29

## TL;DR

This study shows that activating TRPV3 channels in bladder cancer cells causes ATP release, suggesting TRPV3 could be a new target for cancer treatment.

## Contribution

The study introduces AV3-1, a novel TRPV3 activator, and identifies functional TRPV3 in bladder cancer cells.

## Key findings

- TRPV3 channels are functionally active in bladder cancer cells.
- Activation of TRPV3 with AV3-1 leads to ATP release in these cells.
- TRPV3 activity is enhanced by cholesterol in bladder cancer cells.

## Abstract

Transient receptor potential vanilloid 3 (TRPV3) is a thermosensitive Ca2+-permeable ion channel that plays essential roles in epithelial barrier function. Although its expression and function have been well characterized in the skin and, to a lesser extent, in the gastrointestinal tract, its role in the urinary bladder has remained unexplored. In this study, TRPV3 was identified in human bladder cancer cell lines, and its functional activation was demonstrated, using a novel small-molecule agonist activator of TRPV3 channel 1 (AV3-1), discovered through medium-throughput screening. AV3-1 activated mouse and human TRPV3 channels with higher potency than known TRPV3 activators in Ca2+ assays and electrophysiological recordings. TRPV3 activation in the KU-19-19 bladder cancer cells stimulated ATP release, which was abolished by pharmacological TRPV3 blockade, confirming target specificity. Cholesterol supplementation further enhanced TRPV3 activity in KU-19-19 cells, a finding of potential relevance given the known dysregulation of cholesterol metabolism in bladder cancer. These results provide the first evidence of functional TRPV3 expression in bladder cancer cells and suggest that TRPV3 may contribute to Ca2+- and cholesterol-dependent signaling pathways. Collectively, these findings support further investigation of TRPV3 as a potential pharmacological target and exploratory biomarker in urothelial carcinoma.

TRPV3 is an ion channel mainly found in the skin. This study has identified the small molecule AV3-1 as a novel TRPV3 activator. Using AV3-1, this study demonstrates TRPV3 expression in bladder cancer cells. TRPV3 activation in these cells triggers ATP release, a signal potentially promoting cancer progression.

## Linked entities

- **Genes:** TRPV3 (transient receptor potential cation channel subfamily V member 3) [NCBI Gene 162514]
- **Chemicals:** cholesterol (PubChem CID 5997)
- **Diseases:** bladder cancer (MONDO:0004986)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** TRPV3 (transient receptor potential cation channel subfamily V member 3) [NCBI Gene 162514] {aka FNEPPK2, OLMS, OLMS1, VRL3}
- **Diseases:** cancer (MESH:D009369), bladder cancer (MESH:D001749), urothelial carcinoma (MESH:D014523)
- **Chemicals:** ATP (MESH:D000255), Ca2+ (-), Cholesterol (MESH:D002784)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12881674/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12881674/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12881674/full.md

---
Source: https://tomesphere.com/paper/PMC12881674